A Randomised, Double-blind, Double-dummy, Placebo-controlled, Five-way Crossover Study to Assess the Effects of Single Oral Doses of SB-681323 (7.5 mg and 25 mg) and Prednisolone (10 mg and 30 mg) on Biomarkers in Induced Sputum and Blood in COPD Patients.

NCT00380133 Phase 1 COMPLETED

This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	COMPLETED
Enrolment	20
Start date	2005-06
Completion	2006-04

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• SB681323
• Prednisolone
• Placebo

Primary outcomes

• Pharmacodynamic effect of single, oral doses of SB-681323 and prednisolone — 20 weeks
  Levels of ex-vivo LPS induced TNFα in whole blood at 1, 2, 6 and 24 hrs post-dose

Countries

United Kingdom